162 related articles for article (PubMed ID: 38534943)
1. Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action.
Sehdev S; Gotfrit J; Elias M; Stein BD
Curr Oncol; 2024 Mar; 31(3):1460-1469. PubMed ID: 38534943
[TBL] [Abstract][Full Text] [Related]
2. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
Gotfrit J; Shin JJW; Mallick R; Stewart DJ; Wheatley-Price P
Oncologist; 2020 Jan; 25(1):e130-e137. PubMed ID: 31506392
[TBL] [Abstract][Full Text] [Related]
3. Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.
Sehdev SR; Rawson NSB; Aseyev OI; Buick CJ; Butler MO; Edwards S; Gill S; Gotfrit JM; Hsia CC; Juergens RA; Manna M; McCarthy JS; Mukherjee SD; Snow SL; Spadafora S; Stewart DJ; Wentzell JR; Wong RPW; Zalewski PG
Curr Oncol; 2024 Mar; 31(4):1803-1816. PubMed ID: 38668039
[TBL] [Abstract][Full Text] [Related]
4. Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada.
Vanderpuye-Orgle J; Erim D; Qian Y; Boyne DJ; Cheung WY; Bebb G; Shah A; Pericleous L; Maruszczak M; Brenner DR
Oncol Ther; 2022 Jun; 10(1):195-210. PubMed ID: 35230672
[TBL] [Abstract][Full Text] [Related]
5. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
6. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
[TBL] [Abstract][Full Text] [Related]
7. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
8. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
9. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
Binder L; Ghadban M; Sit C; Barnard K
Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
[TBL] [Abstract][Full Text] [Related]
10. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
11. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
12. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
[TBL] [Abstract][Full Text] [Related]
13. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
Ho C; Lim HJ; Regier DA
Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
[TBL] [Abstract][Full Text] [Related]
14. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
Chabot I; Rocchi A
Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
[TBL] [Abstract][Full Text] [Related]
15. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
16. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
Fontrier AM; Kanavos P
Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
[TBL] [Abstract][Full Text] [Related]
17. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
MacPhail C; Snow S
Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
[TBL] [Abstract][Full Text] [Related]
18. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
20. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
Rocchi A; Menon D; Verma S; Miller E
Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
